Multi User License - $2,999
In order to actively stimulate the retina, the Wearable Device for Myopia Control projects myopically-defocused virtual pictures into the peripheral visual field using micro LEDs. This reduces the gradual lengthening of the eye in myopic patients. This device, which makes use of multifocal contact lens technology, uses light that has been myopically defocused by the non-central power of the contact lens to passively excite the entire peripheral retina.
The electronic glasses-based Kubota Glasses technology uses nanotechnology to actively stimulate the retina for shorter periods of time while retaining excellent central vision and not interfering with daily activities. This gadget aims to slow the onset of myopia.
The invention can also objectively and accurately generate the eye health indication result through a scientific calculation scheme, effectively improve eye habit, control the close distance and Duration, and manage enough outdoor time and frequency. It is more suitable for more perfect myopia prevention and control by the user wearing the device for a long time.
The Global Wearable Device for Myopia Control market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
A milestone was completed by Kubota Vision, a clinical-stage specialty ophthalmology business and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. The company created the first wearable prototype in the form of a pair of glasses using Kubota Glasses technology.
This product, which makes use of multifocal contact lens technology, uses light that has been myopically defocused by the contact lens’ non-central power to passively excite the entire peripheral retina. With their electronic glasses-based Kubota Glasses technology, which uses nanotechnology, the company aims to slow the onset of myopia by actively stimulating the retina for shorter periods of time while retaining excellent central vision and not interfering with daily activities.
An exclusive licence agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation, has been signed between Santen SA and Sydnexis Inc., a biopharmaceutical company focused on the development of treatments for the treatment of progressive myopia. SYD-101 is a 0.01% and 0.03% low-dose atropine sulphate ophthalmic solution under investigation that aims to increase treatment continuity by achieving efficacy, stability, and pain relief.
SYD-101 is an investigational low-dose atropine formulation built to be pharmacologically stable without requiring the pH to be lowered in order to reach a shelf life of up to three years at room temperature. This is due to its distinctive and proprietary formulation.
© Copyright 2017-2022. Mobility Foresights. All Rights Reserved.